• Order to parcel locker

    Order to parcel locker
  • easy pay

    easy pay
  • Reduced price
Persistent Drug Shortages in the United States: Analyses & Strategies

Persistent Drug Shortages in the United States: Analyses & Strategies

9781633211742
875.64 zł
788.07 zł Save 87.57 zł Tax included
Lowest price within 30 days before promotion: 788.07 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
From prolonged duration of a disease, to permanent injury, to death, drug shortages have led to harmful outcomes for patients of all ages. Over the last decade, an increasing number of prescription drugs -- including life-saving and life-sustaining drugs -- have been in short supply, preventing health care providers and patients from accessing medications that are essential for treatment. During shortages, providers -- including hospitals, physicians, and pharmacists -- may have to use medications that could be less effective for treating conditions or carry unwanted side-effects, if alternatives are available at all. The immediate cause of drug shortages can generally be traced to a manufacturer halting or slowing production to address quality problems, triggering a supply disruption. Other manufacturers have a limited ability to respond to supply disruptions due to constrained manufacturing capacity. This book reviews the trends in recent drug shortages and describes what is known about their effect on patients and providers; examines the causes of drug shortages; and evaluates the progress FDA has made in addressing drug shortages.
Product Details
74619
9781633211742
9781633211742

Data sheet

Publication date
2014
Issue number
1
Cover
hard cover
Pages count
160
Dimensions (mm)
180.00 x 260.00
Weight (g)
374
  • Preface; Drug Shortages:: Public Health Threat Continues, Despite Efforts to Help Ensure Product Availability; Statement of Douglas C Throckmorton, Deputy Director of Regulatory Programs, U.S. Food & Drug Administration. Hearing on Examining Drug Shortages & Recent Efforts to Address Them; Strategic Plan for Preventing & Mitigating Drug Shortages; FDAs Contribution to the Drug Shortage Crisis; Index.
Comments (0)